article thumbnail

Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes

Express Pharma

It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1

article thumbnail

Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

PharmaVoice

The combo therapy topped $10 billion in revenue last year for the first time since its approval in 2019. In general, the megablockbuster trend is skewing toward drugs that reach a wider range of patients, such as checkpoint inhibitors like Keytruda and GLP-1 weight loss and diabetes medications. billion last year.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Therapeutic Guidelines, Australian Medicines Handbook and APF

RX Note

Beyond these official sources, various healthcare societies and associations also contribute by publishing practical guides relevant to their specific disciplines.

article thumbnail

Reimagining Pharmacy Workforce Development: The CPA Academy

Commonwealth Pharmacists Association

The pharmacist in Malaysia, inspiring global peers with their fresh approach to diabetes care. It was a bold, but modest, step – funded by a small grant, but driven by a big ambition: to expand equitable access to meaningful, high-quality professional development for pharmacists, particularly in historically under-resourced settings.

article thumbnail

AZ boasts phase 3 win for self-administered gMG drug

pharmaphorum

Skip to main content Thursday 24 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

November 21, 2019. Effect of acalabrutinib in combination with bendamustine plus rituximab on survival endpoints in older patients with mantle cell lymphoma: insights from the ECHO trial. healthbook TIMES Onco Hema. 2024;22(4):22-29. doi:10.36000/HBT.OH.2024.22.163 ClinicalTrials.gov. Updated February 19, 2025. Accessed May 14, 2025.